Second-order map
Exploratory — reasoned, hypothetical relationships for research, not investment advice.
- LLYCatalyst
Eli Lilly and Company
Q2 2026 results with first full-quarter read on oral GLP-1 Foundayo (orforglipron) reframe oral delivery as the primary competitive axis, triggering an industry-wide wave of GLP-1 NDA filings and formulation work
- CERTSpotlight subject
Certara, Inc.
Primary Spotlight subject: as multiple sponsors race to file oral/next-gen GLP-1 formulations concurrently, Certara's biosimulation and expedited pharmacometrics regulatory-submission service sits at the model-informed drug development bottleneck every filer must activate
- SLP
Simulations Plus, Inc.
If concurrent oral-GLP-1 filings expand demand for PBPK/absorption modeling, a fellow model-informed drug development software vendor could see spillover formulation-simulation workload
- SDGR
Schrodinger, Inc.
Oral small-molecule GLP-1 optimization (orforglipron is non-peptide) shifts competition toward computational molecular design, where physics-based discovery platforms may gain relevance
- MEDP
Medpace Holdings, Inc.
A surge of next-gen GLP-1 programs entering clinical stages could raise demand for CRO trial-execution services complementary to Certara's regulatory modeling
- IQV
IQVIA Holdings Inc.
Broad regulatory/clinical-analytics and submission infrastructure provider that benefits if the industry activates many parallel GLP-1 development workflows
- NVO
Novo Nordisk A/S
Direct competitive filer: Lilly's oral read forces the incumbent GLP-1 rival to accelerate its own oral and next-gen formulation filings, adding to the concurrent regulatory workload
Contract oral-formulation / bioavailability-enhancement specialists
If oral peptide/small-molecule delivery becomes the race, sponsors may outsource permeation-enhancer and formulation development to specialized CDMOs
- CTLT
Catalent (formulation/CDMO services)
Oral solid-dose and specialized delivery formulation demand could rise as multiple GLP-1 oral programs need manufacturing scale-up support
- WST
West Pharmaceutical Services, Inc.
A shift from injectable to oral formats reshapes containment/delivery-component demand, an inferential swing in the drug-packaging supply chain
- AMGN
Amgen Inc.
Sibling second-order filer advancing its own obesity candidates: intensified oral-GLP-1 competition pressures Amgen to activate regulatory-science and formulation optimization workflows too
API / peptide manufacturing suppliers
Scaling multiple next-gen obesity candidates could increase upstream active-ingredient and peptide-synthesis sourcing needs
- TMO
Thermo Fisher Scientific Inc.
Broad lab instrumentation, analytics and CDMO exposure positions it to benefit if many sponsors simultaneously expand formulation and bioanalytical work
- DHR
Danaher Corporation
Bioprocessing and analytical-tools franchise could see lateral demand if a multi-sponsor GLP-1 development surge lifts overall pharma R&D consumables
Take it further
Copy the analysis below into your own AI tool to pressure-test the reasoning and push it further.
Today's crowd trade is straightforward — investors will be closely watching the sales performance of Mounjaro and Zepbound when Eli Lilly reports its second-quarter 2026 results alongside the first commercial read on Foundayo (orforglipron), which launched in April and receives its first full-quarter commercial update today. The headline machinery around Eli Lilly is loud, but the durable second-order read belongs one step removed — in the biosimulation and regulatory science infrastructure that every competing GLP-1 filer must now activate. Oral delivery, not just higher numbers, is now a primary axis of competition , which means a wave of new NDA filings and formulation optimization work is not a distant possibility but an imminent workflow burden across the industry. Certara sits precisely at that bottleneck: from molecule to market, Certara integrates science, technology, strategic and regulatory expertise, and navigates complex regulatory landscapes with AI-driven tools while reducing development risk through predictive science and model-informed strategies . Certara recently launched an expedited Pharmacometrics regulatory submission service that cuts submission timelines in half — a capability that is structurally more valuable in a race where multiple sponsors are filing oral and next-generation GLP-1 formulations concurrently than in any single-drug cycle.